How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
20
OTLK Quote, Financials, Valuation and Earnings
Last price:
$0.43
Seasonality move
:
-3.7%
Day range:
$0.38 - $0.44
52-week range:
$0.38 - $3.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.27x
P/B ratio:
--
Volume:
1.2M
Avg. volume:
9.1M
1-year change:
-75.18%
Market cap:
$27.5M
Revenue:
$1.4M
EPS (TTM):
-$0.57
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics, Inc.
|
$3.9M | -$0.17 | -- | -89.12% | $6.83 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.11 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.34% | 90.44% | $14.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$55.4M | $0.04 | 37.57% | 101.01% | $3.17 |
|
NEOG
Neogen Corp.
|
$208.4M | $0.07 | -7.41% | 800% | $11.67 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics, Inc.
|
$0.43 | $6.83 | $27.5M | -- | $0.00 | 0% | 8.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.11 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
CRMD
CorMedix, Inc.
|
$7.69 | $14.86 | $605.9M | 3.75x | $0.00 | 0% | 2.59x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.30 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.32x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$4.56 | $3.17 | $741.8M | 29.51x | $0.00 | 0% | 2.27x |
|
NEOG
Neogen Corp.
|
$10.80 | $11.67 | $2.3B | 2,124.15x | $0.00 | 0% | 2.66x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OTLK
Outlook Therapeutics, Inc.
|
-1392.36% | 1.816 | 49.88% | 0.34x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
179.07% | 1.269 | 280.72% | 1.08x |
|
NEOG
Neogen Corp.
|
27.37% | 2.120 | 60.96% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OTLK
Outlook Therapeutics, Inc.
|
$1M | -$15.7M | -- | -- | -1046.22% | -$11.9M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
IRWD
Ironwood Pharmaceuticals, Inc.
|
$121.6M | $77.7M | 9.89% | -- | 63.64% | $47.6M |
|
NEOG
Neogen Corp.
|
$83.8M | $748K | -18.95% | -25.93% | 0.33% | $7.8M |
Outlook Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns OTLK or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 25.76%. Outlook Therapeutics, Inc.'s return on equity of -- beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics, Inc.68.83% -$0.55 -$2.5M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About OTLK or ACAD?
Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1491.37%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.11 which suggests that it could grow by 32.03%. Given that Outlook Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics, Inc.2 2 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is OTLK or ACAD More Risky?
Outlook Therapeutics, Inc. has a beta of 0.102, which suggesting that the stock is 89.777% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock OTLK or ACAD?
Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or ACAD?
Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 8.27x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics, Inc.8.27x -- $1.5M -$20.2M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns OTLK or CRMD?
CorMedix, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 49.9%. Outlook Therapeutics, Inc.'s return on equity of -- beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics, Inc.68.83% -$0.55 -$2.5M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About OTLK or CRMD?
Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1491.37%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that Outlook Therapeutics, Inc. has higher upside potential than CorMedix, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics, Inc.2 2 0 CRMDCorMedix, Inc.4 0 0 -
Is OTLK or CRMD More Risky?
Outlook Therapeutics, Inc. has a beta of 0.102, which suggesting that the stock is 89.777% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock OTLK or CRMD?
Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or CRMD?
Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 8.27x versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics, Inc.8.27x -- $1.5M -$20.2M CRMDCorMedix, Inc.2.59x 3.75x $104.3M $108.6M
-
Which has Higher Returns OTLK or FOLD?
Amicus Therapeutics, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 10.24%. Outlook Therapeutics, Inc.'s return on equity of -- beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics, Inc.68.83% -$0.55 -$2.5M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About OTLK or FOLD?
Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1491.37%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.4%. Given that Outlook Therapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics, Inc.2 2 0 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is OTLK or FOLD More Risky?
Outlook Therapeutics, Inc. has a beta of 0.102, which suggesting that the stock is 89.777% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock OTLK or FOLD?
Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or FOLD?
Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 8.27x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics, Inc.8.27x -- $1.5M -$20.2M FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M
-
Which has Higher Returns OTLK or IRWD?
Ironwood Pharmaceuticals, Inc. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of 32.84%. Outlook Therapeutics, Inc.'s return on equity of -- beat Ironwood Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics, Inc.68.83% -$0.55 -$2.5M IRWDIronwood Pharmaceuticals, Inc.99.61% $0.23 $334.1M -
What do Analysts Say About OTLK or IRWD?
Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1491.37%. On the other hand Ironwood Pharmaceuticals, Inc. has an analysts' consensus of $3.17 which suggests that it could fall by -30.56%. Given that Outlook Therapeutics, Inc. has higher upside potential than Ironwood Pharmaceuticals, Inc., analysts believe Outlook Therapeutics, Inc. is more attractive than Ironwood Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics, Inc.2 2 0 IRWDIronwood Pharmaceuticals, Inc.0 4 0 -
Is OTLK or IRWD More Risky?
Outlook Therapeutics, Inc. has a beta of 0.102, which suggesting that the stock is 89.777% less volatile than S&P 500. In comparison Ironwood Pharmaceuticals, Inc. has a beta of 0.172, suggesting its less volatile than the S&P 500 by 82.759%.
-
Which is a Better Dividend Stock OTLK or IRWD?
Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ironwood Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Ironwood Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or IRWD?
Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Ironwood Pharmaceuticals, Inc. quarterly revenues of $122.1M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Ironwood Pharmaceuticals, Inc.'s net income of $40.1M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Ironwood Pharmaceuticals, Inc.'s PE ratio is 29.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 8.27x versus 2.27x for Ironwood Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics, Inc.8.27x -- $1.5M -$20.2M IRWDIronwood Pharmaceuticals, Inc.2.27x 29.51x $122.1M $40.1M
-
Which has Higher Returns OTLK or NEOG?
Neogen Corp. has a net margin of -1338.77% compared to Outlook Therapeutics, Inc.'s net margin of -7.09%. Outlook Therapeutics, Inc.'s return on equity of -- beat Neogen Corp.'s return on equity of -25.93%.
Company Gross Margin Earnings Per Share Invested Capital OTLKOutlook Therapeutics, Inc.68.83% -$0.55 -$2.5M NEOGNeogen Corp.37.29% -$0.07 $2.9B -
What do Analysts Say About OTLK or NEOG?
Outlook Therapeutics, Inc. has a consensus price target of $6.83, signalling upside risk potential of 1491.37%. On the other hand Neogen Corp. has an analysts' consensus of $11.67 which suggests that it could grow by 8.03%. Given that Outlook Therapeutics, Inc. has higher upside potential than Neogen Corp., analysts believe Outlook Therapeutics, Inc. is more attractive than Neogen Corp..
Company Buy Ratings Hold Ratings Sell Ratings OTLKOutlook Therapeutics, Inc.2 2 0 NEOGNeogen Corp.1 2 0 -
Is OTLK or NEOG More Risky?
Outlook Therapeutics, Inc. has a beta of 0.102, which suggesting that the stock is 89.777% less volatile than S&P 500. In comparison Neogen Corp. has a beta of 1.980, suggesting its more volatile than the S&P 500 by 98.002%.
-
Which is a Better Dividend Stock OTLK or NEOG?
Outlook Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Outlook Therapeutics, Inc. pays -- of its earnings as a dividend. Neogen Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OTLK or NEOG?
Outlook Therapeutics, Inc. quarterly revenues are $1.5M, which are smaller than Neogen Corp. quarterly revenues of $224.7M. Outlook Therapeutics, Inc.'s net income of -$20.2M is lower than Neogen Corp.'s net income of -$15.9M. Notably, Outlook Therapeutics, Inc.'s price-to-earnings ratio is -- while Neogen Corp.'s PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Outlook Therapeutics, Inc. is 8.27x versus 2.66x for Neogen Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OTLKOutlook Therapeutics, Inc.8.27x -- $1.5M -$20.2M NEOGNeogen Corp.2.66x 2,124.15x $224.7M -$15.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 7
Bill Holdings, Inc. [BILL] is up 37.11% over the past day.
Buy
75
PRLB alert for Feb 7
Proto Labs, Inc. [PRLB] is up 28.33% over the past day.
Sell
30
MSTR alert for Feb 7
Strategy, Inc. [MSTR] is up 26.08% over the past day.
